• POSB351 A Prospective Observational Study to Determine the Safety, Efficacy, and Toxicity Profile of Paclitaxel in Patients Receiving Weekly and Three Weekly Doses

    Jan 1, 2022, 00:00

  • POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK

    Jan 1, 2022, 00:00

  • POSC69 Healthcare Resource Consumption Associated with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in Italy

    Jan 1, 2022, 00:00

  • A Pregnant Pause: Rethinking Economic Evaluation in Contraception and Pregnancy

    Jan 1, 2022, 00:00

  • POSA192 Disease Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: Signs and Symptoms

    Jan 1, 2022, 00:00

  • POSC343 Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life (QOL) in the United States (US): Systematic Literature Review and Synthesis

    Jan 1, 2022, 00:00

  • POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada

    Jan 1, 2022, 00:00

  • POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France

    Jan 1, 2022, 00:00

  • POSB340 Availability of Published Health-Related Quality of Life (HRQOL) Data for Patients Receiving First-Line (1L) Treatment for Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSA238 Hospital Length of Stay and Antibiotic Prescription Practices for Patients Diagnosed with Gram Negative Infections - Evidence from Hospitals in Romania

    Jan 1, 2022, 00:00

  • POSB99 The Cost-Effectiveness of Biologic/Targeted Synthetic/Biosimilar Disease Modifying Antirheumatic Drugs: A Systematic Review

    Jan 1, 2022, 00:00

  • POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study

    Jan 1, 2022, 00:00

  • POSC141 Evaluation of the Long-Term Cost-Effectiveness of Ideglira Versus Liraglutide for Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs in China

    Jan 1, 2022, 00:00

  • POSB166 Exploring the Impact of Heterogeneity in Economic Evaluations: Current Practice and Implications

    Jan 1, 2022, 00:00

  • POSA11 Ceftolozane-Tazobactam for the Treatment of Complicated Infections in Hospital Settings - Results from a French Real-World Study

    Jan 1, 2022, 00:00

  • POSA209 The Role of Economic Evaluation in the P R in Italy

    Jan 1, 2022, 00:00

  • POSB92 Potential Budget Impact of Negative Pressure Wound Therapy with Instillation and Dwell Versus Control Therapy Across Multiple Geographies

    Jan 1, 2022, 00:00

  • POSC199 A Retrospective Database Analysis of Erythropoiesis-Stimulating Agent Treatment Patterns and Associated Healthcare Resource Use in Non–Dialysis-Dependent Chronic Kidney Disease Patients with Anaemia in Japan

    Jan 1, 2022, 00:00

  • POSB369 Development of the Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure

    Jan 1, 2022, 00:00

  • POSB193 COVID-19 Vaccine Development Pipeline: 2021

    Jan 1, 2022, 00:00

  • POSA306 Recommended Approaches for Analyzing Clinical Outcomes Assessment Data from Oncology Trials for Different Stakeholders

    Jan 1, 2022, 00:00

  • POSA121 Modelling Long-Term Outcomes and Mortality Risk for Post-Stroke Spasticity Patients on Abobotulinumtoxina Treatment and Rehabilitation Therapy

    Jan 1, 2022, 00:00

  • POSB382 Perceptions about Biosimilar Medicines Among Belgian Ambulatory Care Patients

    Jan 1, 2022, 00:00

  • POSB322 The Goal Attainment Scaling Method Is Robust to Violations of Normality in Goal Scales: A Simulation Study

    Jan 1, 2022, 00:00

  • POSC209 Cost of Treatment with Biosimilars - Case with Rituximab in Oncohematology

    Jan 1, 2022, 00:00

  • POSA428 The Impact of Treatment Effect Parameterization in Mixture Cure Models on Survival Estimates and Uncertainty

    Jan 1, 2022, 00:00

  • POSB30 Systematic Literature Review of Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems

    Jan 1, 2022, 00:00

  • POSA195 Assessment of Consumption of Antidepressant Drugs in Ukraine in 2015-2019

    Jan 1, 2022, 00:00

  • POSB378 Health State Utilities Associated with Hyperphagia

    Jan 1, 2022, 00:00

  • POSA312 Exploring Health Related Factors Indicating Susceptibility to COVID19

    Jan 1, 2022, 00:00

  • POSA168 Meta-Analysis and Cost-Effectiveness Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy for the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

    Jan 1, 2022, 00:00

  • POSA113 The Cost Analysis of the Environmental Impacts of Surgical Site Infection from the Perspective of NHS England

    Jan 1, 2022, 00:00

  • POSB305 Assessing the Reliability and Validity of an Instrument Used to Measure Student Pharmacists' Experiences of Teamwork in a Quality Improvement Course

    Jan 1, 2022, 00:00

  • POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies

    Jan 1, 2022, 00:00

  • POSA188 Epidemiological Disease Burden of Non-Insulin-Dependent Diabetes with Peripheral Circulatory Complications Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB140 Healthcare Utilization and Costs of Human Papillomavirus (HPV) Associated Anogenital Diseases in Young Women: An Analysis of Statutory Health Insurance Claims Data from Germany

    Jan 1, 2022, 00:00

  • P34 Use of Social Media Listening (SML) Methods for Understanding the Patient Experience of Chronic Disease: A Scoping Review

    Jan 1, 2022, 00:00

  • POSB423 Incident Versus Prevalent Population: Review of Guidelines to Estimate the Eligible Population for Budget Impact Analysis

    Jan 1, 2022, 00:00

  • POSA213 Product Development Partnerships (PDPS) and Pharmaceutical Innovation

    Jan 1, 2022, 00:00

  • POSB82 Annual Health Insurance Treatment Cost of Malignant Neoplasm of Other and Ill-Defined Sites in the LIP, Oral Cavity, and Pharynx Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB249 Retrospective Analysis of Real-World Clinical Outcomes and Healthcare Resource Consumption in Patients with Chronic Kidney Disease With and Without Secondary Hyperparathyroidism in Italy

    Jan 1, 2022, 00:00

  • POSC60 Assessing the Pattern of Healthcare Costs Among Older United States Adults with Varying Pain Severities

    Jan 1, 2022, 00:00

  • POSC146 Cost-Effectiveness of Adherence in Newly Treated Tuberculosis Patients Using Discrete Event Simulation

    Jan 1, 2022, 00:00

  • POSC151 Cost-Effectiveness Analysis of Ribociclib in Ecuadorian Women with Advanced Breast Cancer

    Jan 1, 2022, 00:00

  • POSA162 Modeling the Ex Ante Real Option Value in a Highly Innovative Therapeutic Area: ALK-Positive Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSA304 Cost-Effectiveness Modelling Structures for Chronic Rhinosinusitis with Nasal Polyps - A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China

    Jan 1, 2022, 00:00

  • POSA294 Meta-Analysis of Effectiveness of Self-Monitoring of Blood Glucose in Type 2 Diabetes

    Jan 1, 2022, 00:00

  • POSA244 First-Line Maintenance (1L MT) Treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Western Europe (WE): Results of the CancerMPact® Survey 2020

    Jan 1, 2022, 00:00

  • Supporting Informal Caregivers of People With Dementia in Cost-Effective Ways: A Systematic Review and Meta-Analysis

    Dec 1, 2021, 00:00

  • Patient Preferences for Anxiety and Depression Screening in Cancer Care: A Discrete Choice Experiment

    Dec 1, 2021, 00:00

  • Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019 [Editor's Choice]

    Dec 1, 2021, 00:00

  • Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data

    Dec 1, 2021, 00:00

  • Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs

    Dec 1, 2021, 00:00

  • Adherence to Clinical Practice Guideline Recommendations on Low-Value Injury Care: A Multicenter Retrospective Cohort Study

    Dec 1, 2021, 00:00

  • Retrospectively Collected EQ-5D-5L Data as Valid Proxies for Imputing Missing Information in Longitudinal Studies

    Dec 1, 2021, 00:00

  • Valuation of Informal Care Provided to People Living With Dementia: A Systematic Literature Review

    Dec 1, 2021, 00:00

  • Table of Contents

    Dec 1, 2021, 00:00

  • A Review of Current Approaches to Defining and Valuing Innovation in Health Technology Assessment [Editor's Choice]

    Dec 1, 2021, 00:00

  • Cost-Effective Analysis of Dual-Energy Computed Tomography for the Diagnosis of Occult Hip Fractures Among Older Adults

    Dec 1, 2021, 00:00

  • Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma

    Dec 1, 2021, 00:00

  • Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents

    Dec 1, 2021, 00:00

  • Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer

    Dec 1, 2021, 00:00

  • Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov [Editor's Choice]

    Dec 1, 2021, 00:00

  • Copyright/Subscription

    Dec 1, 2021, 00:00

  • Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020

    Dec 1, 2021, 00:00

  • Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study

    Dec 1, 2021, 00:00

  • Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? [Editor's Choice]

    Dec 1, 2021, 00:00

  • Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

    Dec 1, 2021, 00:00

  • Editorial Board

    Nov 29, 2021, 08:32

  • The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study [Editor's Choice]

    Nov 1, 2021, 00:00

  • Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?

    Nov 1, 2021, 00:00

  • Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories

    Nov 1, 2021, 00:00

  • Table of Contents

    Nov 1, 2021, 00:00

  • Patient Self-Reported Health, Clinical Quality, and Patient Satisfaction in English Primary Care: Practice-Level Longitudinal Observational Study

    Nov 1, 2021, 00:00

  • Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations [Editor's Choice]

    Nov 1, 2021, 00:00

  • Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses

    Nov 1, 2021, 00:00

  • Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis

    Nov 1, 2021, 00:00

  • Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

    Nov 1, 2021, 00:00

  • Cost-Effectiveness of Magnetic Resonance Imaging-Guided Thrombolysis for Patients With Stroke With Unknown Time of Onset

    Nov 1, 2021, 00:00

  • Costing of Essential Health Service Packages: A Systematic Review of Methods From Developing Economies

    Nov 1, 2021, 00:00

  • Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic

    Nov 1, 2021, 00:00

  • Copyright/Subscription

    Nov 1, 2021, 00:00

  • Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates Under Contingent Scenarios [Editor's Choice]

    Nov 1, 2021, 00:00

  • Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective

    Nov 1, 2021, 00:00

  • Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review [Editor's Choice]

    Nov 1, 2021, 00:00

  • A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions

    Nov 1, 2021, 00:00

  • Impact of Persisting Amblyopia on Socioeconomic, Health, and Well-Being Outcomes in Adult Life: Findings From the UK Biobank

    Nov 1, 2021, 00:00

  • Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study

    Nov 1, 2021, 00:00

  • Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

    Nov 1, 2021, 00:00

  • Editorial Board

    Oct 26, 2021, 08:19

  • Government, Big Pharma, and the People: A Century of Dis-Ease. By Smith MC, Kolassa EM, Pray WS. Routledge. Taylor & Francis Group; 2021.

    Oct 5, 2021, 16:04

  • Editorial Board

    Oct 4, 2021, 17:53

  • Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy

    Oct 1, 2021, 00:00

  • Toward Better Data Dashboards for US Drug Value Assessments [Editor's Choice]

    Oct 1, 2021, 00:00

  • A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

    Oct 1, 2021, 00:00

  • How Much Is a Human Life Worth? A Systematic Review [Editor's Choice]

    Oct 1, 2021, 00:00

  • Quantifying Value of Hope [Editor's Choice]

    Oct 1, 2021, 00:00

  • Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL

    Oct 1, 2021, 00:00

  • Development and Psychometric Testing of the Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale

    Oct 1, 2021, 00:00

  • Copyright/Subscription

    Oct 1, 2021, 00:00

  • Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

    Oct 1, 2021, 00:00

  • Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance [Editor's Choice]

    Oct 1, 2021, 00:00

  • Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma

    Oct 1, 2021, 00:00

  • How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations [Editor's Choice]

    Oct 1, 2021, 00:00

  • Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective

    Oct 1, 2021, 00:00

  • Table of Contents

    Oct 1, 2021, 00:00

  • Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach

    Oct 1, 2021, 00:00

  • Estimation of the Width of Uncertainty in Care Consumption and Costs When Using Common Data Collection Tools in Economic Evaluations: A Benchmark for Sensitivity Analyses

    Oct 1, 2021, 00:00

  • Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure

    Oct 1, 2021, 00:00

  • Encouraging Mammograms Using Behavioral Economics: A Randomized Controlled Trial in Chile

    Oct 1, 2021, 00:00

  • Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy

    Oct 1, 2021, 00:00

  • Influence of Shared Decision Making on Decisional Conflict and Regret in Postpartum Mother–Infant Care: A Randomized Controlled Trial

    Sep 1, 2021, 00:00

  • Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? [Editor's Choice]

    Sep 1, 2021, 00:00

  • Reference Values and Psychometric Properties of the Quality of Life After Traumatic Brain Injury-Overall Scale in Italy, The Netherlands, and the United Kingdom

    Sep 1, 2021, 00:00

  • Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States

    Sep 1, 2021, 00:00

  • Mapping EQ-5D-3L to EQ-5D-5L [Editor's Choice]

    Sep 1, 2021, 00:00

  • Branded Price Variation in the United States Drug Market, 2010 to 2019

    Sep 1, 2021, 00:00

  • Cost-Effectiveness of Pulmonary Rehabilitation in Patients With Bronchial Asthma: An Analysis of the EPRA Randomized Controlled Trial

    Sep 1, 2021, 00:00

  • Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs [Editor's Choice]

    Sep 1, 2021, 00:00

  • To What Extent Do Patient Preferences Differ From General Population Preferences? [Editor's Choice]

    Sep 1, 2021, 00:00

  • Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact

    Sep 1, 2021, 00:00

  • New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey

    Sep 1, 2021, 00:00

  • Measuring Financial Burden in Families of Children Living With Life-Limiting Conditions: A Scoping Review of Cost Indicators and Outcome Measures

    Sep 1, 2021, 00:00

  • Opioid Prescribing in United States Health Systems, 2015 to 2019

    Sep 1, 2021, 00:00

  • Table of Contents

    Sep 1, 2021, 00:00

  • Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing

    Sep 1, 2021, 00:00

  • Copyright/Subscription

    Sep 1, 2021, 00:00

  • Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations

    Sep 1, 2021, 00:00

  • Drug Prices and Value of Oncology Drugs in Italy

    Sep 1, 2021, 00:00

  • Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model

    Sep 1, 2021, 00:00

  • Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

    Sep 1, 2021, 00:00

  • Editorial Board

    Aug 25, 2021, 09:42

  • Copyright/Subscription

    Aug 9, 2021, 09:02

  • Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients

    Aug 1, 2021, 00:00

  • Mitigating Nonattendance Using Clinic-Resourced Incentives Can Be Mutually Beneficial: A Contingency Management-Inspired Partially Observable Markov Decision Process Model

    Aug 1, 2021, 00:00

  • Mapping World Health Organization Quality of Life–BREF Onto 5-Level EQ-5D in Thai Patients With Chronic Diseases

    Aug 1, 2021, 00:00

  • Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation

    Aug 1, 2021, 00:00

  • Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review

    Aug 1, 2021, 00:00

  • How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments

    Aug 1, 2021, 00:00

  • Editorial Board

    Aug 1, 2021, 00:00

  • Author Reply

    Aug 1, 2021, 00:00

  • Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review

    Aug 1, 2021, 00:00

  • Systematic Review on Pain-Related Outcome Domains After Sternotomy: A First Step Toward the Development of a Core Outcome Set

    Aug 1, 2021, 00:00

  • Table of Contents

    Aug 1, 2021, 00:00

  • Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis [Editor's Choice]

    Aug 1, 2021, 00:00

  • Indirect Economic Burden of Sickle Cell Disease [Editor's Choice]

    Aug 1, 2021, 00:00

  • Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings

    Aug 1, 2021, 00:00

  • Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire [Editor's Choice]

    Aug 1, 2021, 00:00

  • The CAPACITI Decision-Support Tool for National Immunization Programs [Editor's Choice]

    Aug 1, 2021, 00:00

  • Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States

    Aug 1, 2021, 00:00

  • Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials [Editor's Choice]

    Aug 1, 2021, 00:00

  • Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches

    Aug 1, 2021, 00:00

  • Inadequate Selection and Treatment Results in Poor Outcomes and Lack of Cost-Effectiveness

    Aug 1, 2021, 00:00

  • Editorial Board

    Jul 6, 2021, 08:41

  • Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland

    Jul 1, 2021, 00:00

  • Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States

    Jul 1, 2021, 00:00

  • Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases

    Jul 1, 2021, 00:00

  • Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis [Editor's Choice]

    Jul 1, 2021, 00:00

  • Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study

    Jul 1, 2021, 00:00

  • Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation

    Jul 1, 2021, 00:00

  • Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of “Better Together in Amsterdam North”

    Jul 1, 2021, 00:00

  • Considerations for Cost-Effectiveness Analysis in Oncology

    Jul 1, 2021, 00:00

  • Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019

    Jul 1, 2021, 00:00

  • Author’s Reply

    Jul 1, 2021, 00:00

  • Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals

    Jul 1, 2021, 00:00

  • Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

    Jul 1, 2021, 00:00

  • Measuring Attitudes About Genomic Medicine: Validation of the Genomic Orientation Scale (GO Scale)

    Jul 1, 2021, 00:00

  • Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis

    Jul 1, 2021, 00:00

  • Copyright/Subscription

    Jul 1, 2021, 00:00

  • Table of Contents

    Jul 1, 2021, 00:00

  • Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies [Editor's Choice]

    Jul 1, 2021, 00:00

  • Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare [Editor's Choice]

    Jul 1, 2021, 00:00

  • Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England

    Jul 1, 2021, 00:00

  • Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections

    Jul 1, 2021, 00:00

  • “Looking Under the Hood” of Anchor-Based Assessment of Clinically Important Change: A Machine Learning Approach [Editor's Choice]

    Jul 1, 2021, 00:00

  • Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia

    Jul 1, 2021, 00:00

  • Editorial Board

    Jun 9, 2021, 10:32

  • Individual's Health - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • PCN159 Prediction of Low-VALUE Cancer Care Among Older Men with Low-Risk Prostate Cancer: A Machine Learning Approach

    Jun 1, 2021, 00:00

  • PCN143 Real-World Assessment of the Treatment Patterns Associated with Un-Resectable Advanced and Metastatic Esophageal Cancer in China

    Jun 1, 2021, 00:00

  • PCN6 Effects of Metformin Use on Progression-Free and Overall Survival of Glioblastoma Cancer Patients: A Systematic Review and Meta-Analysis

    Jun 1, 2021, 00:00

  • PCN124 Potential for Earlier Cancer Diagnosis to Reduce Cancer Deaths:Differences By Sex and Race/Ethnicity

    Jun 1, 2021, 00:00

  • PCV26 ALL-Cause and Bleeding Costs of Patients Initiating P2Y12 Inhibitors, Fxa Inhibitors, and Dabigatran

    Jun 1, 2021, 00:00

  • PIH18 IMPACT of PCP Screening on EARLY Detection of Pediatric Mental Disorder

    Jun 1, 2021, 00:00

  • PCN62 Real-World Costs of FRONT-LINE Treatment for Peripheral T-Cell Lymphoma in France, Germany, and the United Kingdom

    Jun 1, 2021, 00:00

  • No Specific Disease - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PNS56 Survey of the Awareness of Pharmacists about Quarantine Measures during the COVID-19 Pandemic

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Medical Technologies

    Jun 1, 2021, 00:00

  • PMU9 Budget Impact Analysis of Expanding Use of Recombinant Human Hyaluronidase-facilitated Subcutaneous Ig Infusion in patients with Primary Immunodeficiencies (PID) in Brazil

    Jun 1, 2021, 00:00

  • PGI7 Correlation between Clinical Outcomes and HTA Decisions in Ulcerative Colitis

    Jun 1, 2021, 00:00

  • PRO12 Early Pricing and Access Forecasting for Orphan Assets - Leveraging a Value-Driven Approach to Price Forecasting

    Jun 1, 2021, 00:00

  • PIN41 The Public Health Implications of Google Trends and News Coverage for COVID-19 in the Early Epidemic Stage: A Multinational Study in Eight Countries

    Jun 1, 2021, 00:00

  • PSU2 IMPACT of Recognized and Unrecognized Iatrogenic Lower Ureteral Injury at Time of Hysterectomy: A Nationwide Populational Database Study

    Jun 1, 2021, 00:00

  • PNS4 The Consequences of Greater Net Price Transparency for Innovative Medicines: Insights from European Experts and Payers

    Jun 1, 2021, 00:00

  • PRO76 Resource Utilization and Costs Among Patients with Glycogen Storage Disease Type Ia (GSDIa)

    Jun 1, 2021, 00:00

  • PUK22 Treatment Adherence and Quality of Life in UK Distal Renal Tubular Acidosis Patients

    Jun 1, 2021, 00:00

  • PIN30 Comparing Two Rotavirus Vaccines Strategies Versus NO Vaccine in China- a Cost-Effectiveness Analysis

    Jun 1, 2021, 00:00

  • EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

    Jun 1, 2021, 00:00

  • No Specific Disease - Conceptual Papers (CP)

    Jun 1, 2021, 00:00

  • PNS43 Have NMPA Priority Review Designations Supported Accelerated Regulatory Approval and Patient Access?

    Jun 1, 2021, 00:00

  • PND3 Improvements in Migraine-specific Quality of Life Questionnaire (MSQ) Domain Scores with Fremanezumab and Galcanezumab in Patients with Multiple Prior Migraine Preventive Treatment Failures: A Network Meta-analysis

    Jun 1, 2021, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    Jun 1, 2021, 00:00

  • Infectious Diseases - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PCN59 Health Utility Values in Small Cell Lung Cancer: A Literature Review

    Jun 1, 2021, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    Jun 1, 2021, 00:00

  • PCN61 Targeted Literature Review (TLR) of the Economic Burden and Cost-Effectiveness of Treatments for Advanced/Metastatic Melanoma

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PNS71 Formulary Decision-Maker Survey on Clinician Familiarity with Value Frameworks

    Jun 1, 2021, 00:00

  • PRO36 Prevalence of Friedreich Ataxia: A Systematic Literature Review

    Jun 1, 2021, 00:00

  • Individual's Health - Patient-Centered Research

    Jun 1, 2021, 00:00

  • PCV17 Cost Analysis of Myocardial Infarction and Ischemic Stroke Using the National Claims Database in Taiwan

    Jun 1, 2021, 00:00

  • PCN127 What Is the IMPACT of the Introduction of Ipilimumab, Pembrolizumab, and Nivolumab on Malignant Melanoma in Nordics?

    Jun 1, 2021, 00:00

  • PCN220 Conceptual Framework of Symptoms and Impacts Experienced By Patients with Nut Carcinoma

    Jun 1, 2021, 00:00

  • PCN27 Real-World Characteristics and Outcomes of Patients with Metastatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan-Based Regimens By Race

    Jun 1, 2021, 00:00

  • PCN102 A Cost Comparison Study to Review Community Versus ACUTE Hospital Models of Nursing Care Delivered to Oncology Patients.

    Jun 1, 2021, 00:00

  • PCN147 Impact of Guideline-Concordant Treatment on Survival Among Older Women with Advanced Ovarian Cancer

    Jun 1, 2021, 00:00

  • Cardiovascular Disorders - Clinical Outcomes

    Jun 1, 2021, 00:00

  • Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios

    Jun 1, 2021, 00:00

  • PCV39 Association between Social Determinants of Health, Heathcare Resource Utilization, Medication Adherence, and Medication Persistence Among Patients with Hypertension

    Jun 1, 2021, 00:00

  • PND38 IMPACT of Remoteness on Cost of Illness of Australians with Multiple Sclerosis

    Jun 1, 2021, 00:00

  • PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database

    Jun 1, 2021, 00:00

  • PCN151 The Geographical Association with LUNG Cancer Incidents, Mortality, and Accessibility of LUNG Cancer Screening in RURAL Appalachia

    Jun 1, 2021, 00:00

  • PMU11 Economic Evaluation of Avatrombopag for Elective Diagnostic Procedure or Surgery of Thrombocytopenia in Adult Patients with Chronic LIVER Disease (CLD) in China

    Jun 1, 2021, 00:00

  • PDG8 Economic Burden of Patients Treated with Dalbavancin in a Spanish Hospital: ECODAL Analysis

    Jun 1, 2021, 00:00

  • PCN94 Budget IMPACT of Changing Nivolumabe Doses: A Simulation in Health Insurance System

    Jun 1, 2021, 00:00

  • PRO61 Health-Related Quality of Life (HRQOL) and Healthcare Resource Use (HCRU) Associated with the Treatment of Pompe Disease (PD): Targeted Literature Reviews

    Jun 1, 2021, 00:00

  • PSY6 Differences in All-Cause Health Care Costs of Alopecia Areata in the United States by Patient Subgroups: A Latent Class Approach

    Jun 1, 2021, 00:00

  • PRO60 The Epworth Sleepiness Scale for Children and Adolescents Is a Fit-for-Purpose Measure of Daytime Sleepiness in Prader-Willi Syndrome: A Qualitative Interview Study

    Jun 1, 2021, 00:00

  • PDG5 Changes in Canadian Guidelines for Conducting Budget IMPACT Analysis

    Jun 1, 2021, 00:00

  • PCN194 Comparing Complex Machine Learning Models to Predict Likelihood of Ovarian Cancer Using Medicare Claims DATA

    Jun 1, 2021, 00:00

  • PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

    Jun 1, 2021, 00:00

  • Rare Process of Care

    Jun 1, 2021, 00:00

  • PDB43 eHealth Use Among Type 2 Diabetics: PRE-COVID Associations with Patient Activation, Preventive Behaviors, and Health Outcomes

    Jun 1, 2021, 00:00

  • PIN5 Immunogenicity and Safety of the COVID-19 Vaccines Compared to Controls in Healthy Adults: A Systematic Review

    Jun 1, 2021, 00:00

  • PMU67 Comparison of Health-Related Quality of Life of Diabetic Adults with and without Cardiovascular Disease in the United States

    Jun 1, 2021, 00:00

  • Rare Orphan Diseases - Clinical Outcomes

    Jun 1, 2021, 00:00

  • PNS42 The Financial Burden of Medicine out of Pocket Payment Among Households in Ethiopia: An Analysis of Trends and Determinants

    Jun 1, 2021, 00:00

  • PDG41 Evaluating the Effectiveness and Safety and Economy of Domestic and Original Tigecycline for Injection in Real-World Based on PSM Method

    Jun 1, 2021, 00:00

  • PND5 Relationship between the Short-Form 12 (SF-12) and Schizophrenia Symptom Rating Scales in a Randomized Controlled Clinical Trial of Paliperidone Palmitate 3 Monthly Formulation

    Jun 1, 2021, 00:00

  • PNS111 Development of the SF-6DV2 Health Utility Survey: Content Validity and Patient Preference

    Jun 1, 2021, 00:00

  • Infectious Diseases - Clinical Outcomes

    Jun 1, 2021, 00:00

  • PUK9 Economic Evaluation of Prostate-Specific Antigen Screening for Prostate Cancer in China

    Jun 1, 2021, 00:00

  • Infectious Diseases - Health Policy Regulatory

    Jun 1, 2021, 00:00

  • PNS63 A Longitudinal Study to Identify Potentially Low-Value Clinical Procedures Using Hospital Episode Statistics Linked to Deprivation and Ethnicity in England, 2014/15-2018/19

    Jun 1, 2021, 00:00

  • CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN)

    Jun 1, 2021, 00:00

  • PIH15 Antimuscarinic Cascade across Individual Cholinesterase Inhibitors in Older Adults with Dementia

    Jun 1, 2021, 00:00

  • PCN200 Automating the Identification of Lines of Therapy from Real-World Data in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

    Jun 1, 2021, 00:00

  • PMS34 LONG- and Short-TERM Disability and Workers' Compensation Trends for Employees with BONE Diseases in the United States

    Jun 1, 2021, 00:00

  • Alternative Medicine Public Health

    Jun 1, 2021, 00:00

  • PUK19 DATA Quality Considerations for Determining the IMPACT of the COVID-19 Pandemic on Outpatient Visits and Procedures in the United States

    Jun 1, 2021, 00:00

  • PCN135 Two-Week-Wait Referral and Mortality of Uterus Cancer

    Jun 1, 2021, 00:00

  • Cancer - Methodological Statistical Research

    Jun 1, 2021, 00:00

  • PMU59 Predictors and Health Related Quality of Life Associated with Renal Diseases in Cancer Patients in United States

    Jun 1, 2021, 00:00

  • PGI8 An Exploratory Analysis of the Survival Benefits in Commercially Insured Patients with Hepatic Encephalopathy (HE) Treated with Rifaximin versus Lactulose Alone using US Claims Data

    Jun 1, 2021, 00:00

  • PND33 A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting

    Jun 1, 2021, 00:00

  • PCN154 Real-World Assessment of the Treatment Patterns, Healthcare Resource Use, and Survival Outcomes Associated with Non-Resectable Advanced Esophageal Cancers in South Korea

    Jun 1, 2021, 00:00

  • PRO16 Clinical and Economic Consequences of the Breakthrough Hemolysis

    Jun 1, 2021, 00:00

  • PSS11 Comparing Patient's Compliance and Persistence on Prostaglandin Analogs Using Real-World Utilization Databases for the Treatment of OPEN-Angle Glaucoma or Ocular Hypertension.

    Jun 1, 2021, 00:00

  • Systemic Disorders/Conditions - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PNS89 WORTH the Weight: Evaluation of Weighting Strategies in Unanchored Matching-Adjusted Indirect Comparison

    Jun 1, 2021, 00:00

  • PCN23 The Development and Validation of a Simulation Model-based Clinical Decision Tool to Support Oncology Practice

    Jun 1, 2021, 00:00

  • PIH40 Screen-Based Media Use among Children and Adolescents: An Application of Unsupervised Topic Modeling

    Jun 1, 2021, 00:00

  • PCN201 Anonymous Online Cannabis Survey Captures Representative National Sample of People with Breast Cancer

    Jun 1, 2021, 00:00

  • Multiple Diseases - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Patient-Centered Research

    Jun 1, 2021, 00:00

  • PRO23 An Observational Cohort Analysis on the Economic IMPACT of Chronic Kidney Disease in Patients with Fabry Disease

    Jun 1, 2021, 00:00

  • PMU48 The IMPACT of COVID-19 on European Health Technology Assessments

    Jun 1, 2021, 00:00

  • Cardiovascular Disorders - Medical Technologies

    Jun 1, 2021, 00:00

  • PCN232 Economic Burden Among Breast Cancer Patients in the United States

    Jun 1, 2021, 00:00

  • PRO4 Uncertainty in Clinical Outcomes in the Treatment of Paediatric Orphan Indications with Licensed Therapies

    Jun 1, 2021, 00:00

  • PMH53 A Machine Learning Approach to Understanding How Patient Engagement with a Prescription Digital Therapeutic Relates to Healthcare Resource Utilization in Opioid Use Disorder

    Jun 1, 2021, 00:00

  • PCN215 Attributes Influencing Choice of Adjuvant Treatment for Muscle-Invasive Urothelial Cancer: Qualitative Research

    Jun 1, 2021, 00:00

  • PRO73 Limitations of Matched Control Groups Using Stabilization Criteria: A Case Study in CAH

    Jun 1, 2021, 00:00

  • PMU36 Effects of the Medicare PART D Comprehensive Medication Review on Medication Adherence Among Beneficiaries with Alzheimer's Disease

    Jun 1, 2021, 00:00

  • PIN23 Costs-Consequences Analysis of Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia in the Brazilian Private Healthcare System

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Organizational Practices

    Jun 1, 2021, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PND29 Scenario Analyses on Major Impactful and Uncertain Inputs of the Cost-Effectiveness Model of Fremanezumab From a Healthcare System Perspective in England

    Jun 1, 2021, 00:00

  • PND58 Health-Related Quality of Life and Caregiver Burden for Caregivers of Individuals with Neurogenic Orthostatic Hypotension

    Jun 1, 2021, 00:00

  • Predicting Potential Prevention Effects on Hospital Burden of Nosocomial Infections: A Multistate Modeling Approach

    Jun 1, 2021, 00:00

  • PDG19 Prescription Opioid Use in Women during Pregnancy - A Retrospective Analysis Using Texas Medicaid Prescription Claims Data

    Jun 1, 2021, 00:00

  • PCN174 Innovative Approaches to Cancer Therapy Provision in the COVID-Era

    Jun 1, 2021, 00:00

  • PCN125 Waste of Resources in Cervical and Breast Cancer Screening in JAPAN

    Jun 1, 2021, 00:00

  • PCN77 Cost-effectiveness analysis of adjuvant FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial

    Jun 1, 2021, 00:00

  • RE2 Modeling the Impact of Drug Pricing Policies on Innovation

    Jun 1, 2021, 00:00

  • PMS29 Qualitative Study to Understand the Patient Experience of Knee Osteoarthritis (OA) and Assess the Content Validity of the Knee Injury and Osteoarthritis Outcome Score (KOOS) and HIP Disability and Osteoarthritis Outcome Score (HOOS) M ...

    Jun 1, 2021, 00:00

  • PMH13 Healthcare Resource Utilization and Costs before and after Long-Acting Injectable Antipsychotic (LAI) Use in Commercially Insured Young Adults with Schizophrenia

    Jun 1, 2021, 00:00

  • PCN81 Economic Evaluation of First-LINE Atezolizumab for Extensive-STAGE SMALL-Cell LUNG Cancer: The Difference between the Standard Parametric MODEL and the Mixture Cure MODEL

    Jun 1, 2021, 00:00

  • PCN83 Healthcare Resource Utilization (HCRU) of Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer (EC/GEJC) Receiving Adjuvant Nivolumab Treatment Versus Placebo:

    Jun 1, 2021, 00:00

  • PMH49 Factors Affecting Medication Nonadherence Among Patients with Psychiatric Illness in Tertiary Care Teaching Hospital in South India

    Jun 1, 2021, 00:00

  • PND35 Modeling The Economic Impact Of Incorporating AbobotulinumtoxinA Into An Institutional Formulary For FDA-Approved Indications

    Jun 1, 2021, 00:00

  • PRS24 Utilizing Blue Cross Blue Shield of Louisiana (BCBSLA) Risk of Hospitalization (ROH) AI Predictive Model to Help Louisiana Identify Patients at High Risk for a COVID-19 Hospital Admission

    Jun 1, 2021, 00:00

  • PDB12 Hospital Burden of Chronic Gout with and without Tophus Insured By Medicaid: A Propensity Score Matched Analysis of in-Patient Claims Database

    Jun 1, 2021, 00:00

  • PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

    Jun 1, 2021, 00:00

  • PMH23 Epidemiology of Acute Agitation Secondary to Schizophrenia and/or Bipolar Disorder in Patients Presenting to Emergency Departments, a Systematic Literature Review

    Jun 1, 2021, 00:00

  • PSS3 Topline Patient-Reported Outcome Results from a Multicenter, Open-Label, Phase 4 Study of Repository Corticotropin Injection in Patients with Refractory Severe Noninfectious Keratitis

    Jun 1, 2021, 00:00

  • PCN172 Evaluation of Real-World Evidence (RWE) Used within Health Technology Assessments (HTA) in Oncology with Pivotal Single-Arm Trials: A Comparative Study of Six HTA Agencies

    Jun 1, 2021, 00:00

  • PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients

    Jun 1, 2021, 00:00

  • PRS17 Economic Impact of COVID-19 Lockdown on Households in Nigeria

    Jun 1, 2021, 00:00

  • PDB11 Real-world cost-effectiveness of SGLT-2 inhibitors versus DPP-4 inhibitors for type 2 diabetes: A modeling study

    Jun 1, 2021, 00:00

  • PUK8 Water: A Prevention Strategy to Decrease the Economic Burden of Recurrent Cystitis Among Women in the United States of America

    Jun 1, 2021, 00:00

  • No Specific Disease - Economic Evaluation

    Jun 1, 2021, 00:00

  • PCN156 Real-World Non-Persistence with Oral Multiple Myeloma Treatments: A Comparative Analysis of Methodologies Using Claims Data

    Jun 1, 2021, 00:00

  • PDB27 An Evaluation of the Use of Psychotropic Agents Among Adults 65 Years or Older with Type 2 Diabetes

    Jun 1, 2021, 00:00

  • PCN71 Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies

    Jun 1, 2021, 00:00

  • No Specific Disease - Health Policy Regulatory

    Jun 1, 2021, 00:00

  • PIN61 Switch Patterns Among Patients Claiming Antifungal Therapies for Onychomycosis in Canada

    Jun 1, 2021, 00:00

  • PCN67 Estimating Cost-Effectiveness of Pembrolizumab in Advanced Esophageal Cancer Based on the Keynote-181 Trial

    Jun 1, 2021, 00:00

  • PNS17 Value of a Comprehensive Ophthalmology Custom Pack in a Canadian Setting

    Jun 1, 2021, 00:00

  • PCN245 Examining Longitudinal Practice Patterns in the use of ANTI-PD-1 and ANTI-PD-L1 Inhibitors as First-Line Therapy in Non-Small Cell Lung Cancer Patients in the US

    Jun 1, 2021, 00:00

  • Disclosure Information

    Jun 1, 2021, 00:00

  • Drugs Statistical Research

    Jun 1, 2021, 00:00

  • Medical Technology Studies

    Jun 1, 2021, 00:00

  • Infectious Diseases - Conceptual Papers (CP)

    Jun 1, 2021, 00:00

  • PMS3 Risk Factors Associated with Falls and Fractures Followed by Opioid Prescription among Privately-Insured Patients with Osteoarthritis

    Jun 1, 2021, 00:00

  • PIN74 Health-Related Quality of Life (HRQoL) in COVID-19 Patients - a Systematic Literature Review

    Jun 1, 2021, 00:00

  • PMU8 The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases

    Jun 1, 2021, 00:00

  • Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017

    Jun 1, 2021, 00:00

  • Urinary/Kidney Disorders - Economic Evaluation

    Jun 1, 2021, 00:00

  • PND2 Efficacy and Safety of Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review

    Jun 1, 2021, 00:00

  • PCV48 Clinical Restrictions in Cardiac Health Technology Assessments

    Jun 1, 2021, 00:00

  • PMU4 Bridging the Gap: Aligning Economic Research With Disease Burden

    Jun 1, 2021, 00:00

  • PRO28 Healthcare Resource Use (HCRU) of Patients with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in France

    Jun 1, 2021, 00:00

  • PSS8 The Economic Burden of Macular Edema (ME) Associated with Non-infectious Uveitis (NIU) – A US Commercial Payer’s Perspective

    Jun 1, 2021, 00:00

  • PNS118 Real World Evidence (RWE) Use in Latin America Healthcare Decision Making: An Stakeholder Survey Analysis.

    Jun 1, 2021, 00:00

  • PNS79 Milestones for HTA Institutionalization in Ukraine Due to International Practice

    Jun 1, 2021, 00:00

  • IN3 Economic VALUE and Health System IMPACT of Remdesivir in Treating Hospitalized COVID-19 Patients in the United States

    Jun 1, 2021, 00:00

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PCN136 Evaluation of the Extent of Real-World Evidence (RWE) Used Within Health Technology Appraisals (HTA) in Oncology: A Comparative Study of Six HTA Agencies

    Jun 1, 2021, 00:00

  • PMS33 Long- and Short-Term Disability and Workers' Compensation Trends for Employees with Systemic Lupus Erythematosus or Connective Tissue Disorders in the United States

    Jun 1, 2021, 00:00

  • PND54 A Comparison of NOS and ROBINS-I Tools for Quality Assessment of Observational Studies

    Jun 1, 2021, 00:00

  • PMU13 Economic Impact of Comorbidities in an Employer-Insured Migraine Population

    Jun 1, 2021, 00:00

  • Cancer - Medical Technologies

    Jun 1, 2021, 00:00

  • PNS75 The Evolution of Payer Perceptions of Icer

    Jun 1, 2021, 00:00

  • PCN107 Economic Burden of Complications Associated with Transthoracic Needle Biopsy of Pulmonary Nodules: A Retrospective Cohort Analysis

    Jun 1, 2021, 00:00

  • PNS9 Estimating Incidence Progressed Patients in Partitioned Survival Models - a Comparison of Three Methodologies

    Jun 1, 2021, 00:00

  • Cancer - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PCN181 Real-World Evidence (RWE) in Reimbursement, Pricing, and Health Technology Assessment (HTA) in ASIA. How CAN Rwe Supplement Trial DATA in Oncology Indications in a Premarketing Setting?

    Jun 1, 2021, 00:00

  • Drugs Generics - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China

    Jun 1, 2021, 00:00

  • ED4 Economic Burden of Attention-Deficit/Hyperactivity Disorder (ADHD) Among Children and Adolescents in the United States (US): A Societal Perspective

    Jun 1, 2021, 00:00

  • PCN84 Comparing the Downstream Costs and Healthcare Utilization Associated with the Use of Low-dose Computed Tomography (LDCT) in Lung Cancer Screening in Patients with and without AlzheimerÂ’s Disease and Related Dementias (ADRD)

    Jun 1, 2021, 00:00

  • PNS22 Real-World DATA of ADR Reports in Signal Detection - DME Perspective

    Jun 1, 2021, 00:00

  • Mental Health - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PMU38 Market Access Trends of Pharmaceutical Products in the EU5 and US (2009-2019)

    Jun 1, 2021, 00:00

  • PDB29 Medication Non-Adherence and Health Literacy Among Medicare Beneficiaries with Type 2 Diabetes

    Jun 1, 2021, 00:00

  • PRO21 Burden of Illness in Patients with Light Chain (AL) Amyloidosis: A Real World Study Using Optum Claims Database

    Jun 1, 2021, 00:00

  • PIN43 Sociodemographic Characteristics Associated with Vaccination for Dengue Fever and Yellow Fever in Brazil: Results from the 2018 National Health and Wellness Survey

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    Jun 1, 2021, 00:00

  • PCN240 Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer

    Jun 1, 2021, 00:00

  • Cardiovascular Disorders - Economic Evaluation

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Methodological Statistical Research

    Jun 1, 2021, 00:00

  • PCN100 Economic Burden in Patients with Metastatic Cervical Cancer: A Truven MarketScan Database Study

    Jun 1, 2021, 00:00

  • Sensory System Disorders - Economic Evaluation

    Jun 1, 2021, 00:00

  • PMS23 Preferences of Patients with Rheumatoid Arthritis Are Diverse and Changeable

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PNS36 VALUE Based Procurement: A Tool to Make Better Purchasing Decisions after COVID-19

    Jun 1, 2021, 00:00

  • PNS7 Ongoing SLRs When Considering HTA Submissions: Rewards and Avoidable Pitfalls

    Jun 1, 2021, 00:00

  • MT3 Assessing the Potential Value of Wearable Digital Health Technologies in Chronic Kidney Disease Using Early HTA Methods

    Jun 1, 2021, 00:00

  • Economic Evaluation of New Models of Care: Does the Decision Change Between Cost-Utility Analysis and Multi-Criteria Decision Analysis?

    Jun 1, 2021, 00:00

  • PBI16 Number Needed to Treat and Incremental Costs per Responder for Biologics in Adult Patients with Active Radiographic Axial Spondyloarthritis in the Russian Federation

    Jun 1, 2021, 00:00

  • PND22 Cost-Utility of Mechanical Thrombectomy after Thrombolysis in Ischemic-Stroke Due to Large Vessel Oclussion in Obras Sociales and Empresas De Medicina Prepaga in Argentina

    Jun 1, 2021, 00:00

  • PNS99 Using an Online Survey to Elicit Preferences in China: Comparison of Different Methods Based on SF-6DV2

    Jun 1, 2021, 00:00

  • PCN244 Supervised Machine Learning for Predicting Mortality in Acute Myeloid Leukemia Patients Using Electronic Health Record Data

    Jun 1, 2021, 00:00

  • Cancer - Patient-Centered Research

    Jun 1, 2021, 00:00

  • PCN184 Understanding the VALUE of Real-World Evidence (RWE) in Health Economics: Are Traditional Systematic Literature Reviews (SLRS) Omitting Key Evidence for Health Technology Assessment (HTA)?

    Jun 1, 2021, 00:00

  • PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections

    Jun 1, 2021, 00:00

  • PCN205 IMPACT of Treatment Adherence on CORE Outcomes in Patients with Colorectal Cancer: A Systematic Review

    Jun 1, 2021, 00:00

  • PCN48 Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

    Jun 1, 2021, 00:00

  • Medical Devices - Medical Technologies

    Jun 1, 2021, 00:00

  • CE3 Systematic Review and Indirect Comparison of PD-(L)1 Inhibitors in Combination with Platinum-Based Doublet Chemotherapy (PT-DC) for the First-Line Treatment of Non-Squamous, Non-Small-Cell Lung Cancer (nsqNSCLC)

    Jun 1, 2021, 00:00

  • PRO66 Health-Related Quality of Life in Persons with Sickle Cell Disease

    Jun 1, 2021, 00:00

  • CE4 Expanding Evidence Base VS Introducing Heterogeneity in Networks for Network Meta-Analyses: A Simulation Study

    Jun 1, 2021, 00:00

  • PRS3 Joint Modelling of Forced Vital Capacity Decline and Time to Hospitalization Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease

    Jun 1, 2021, 00:00

  • PRO8 Effectiveness and Safety of Teriflunomide in Patients with Multiple Sclerosis: A Real-World Study from WEST China Hospital, China

    Jun 1, 2021, 00:00

  • PCN7 Analysis of Individual-Level Association of Progression-Free Survival (PFS) and Time to Treatment Failure (TTF) with Overall Survival (OS) for Previously Untreated Advanced Renal Cell Carcinoma Patients in the CheckMate 214 Trial

    Jun 1, 2021, 00:00

  • PIH22 Efficacy Of Telephone-Based Educational Intervention On Knowledge Transfer Of COVID-19 Related Health Topics To Elderly Citizens In Hong Kong: A Pilot Study

    Jun 1, 2021, 00:00

  • PIN35 Prevalence of COVID-19 vs. Seasonal Influenza: A Population-Based National Survey of US Adults

    Jun 1, 2021, 00:00

  • PND15 Health Care Resource Utilization and Costs Among Patients with Essential Tremor: A Retrospective Observational Study in a United States Commercially Insured and Medicare Advantage Population

    Jun 1, 2021, 00:00

  • Surgery - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PCN18 Cetuximab Versus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Effectiveness and Patient-Reported Outcomes Multicohort Study

    Jun 1, 2021, 00:00

  • PCN193 Assessing the Impact of Modeling Non-Disease-Related Mortality on Long-Term Survivorship Rates in Previously Untreated Advanced Melanoma: A Case Study from CheckMate 067

    Jun 1, 2021, 00:00

  • PIH7 Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction

    Jun 1, 2021, 00:00

  • PIN67 Real-Time Analysis of COVID-19 DATA Using Sequential Monte Carlo Methods

    Jun 1, 2021, 00:00

  • PRO38 Twenty Years of Clinical Trials in Duchenne Muscular Dystrophy: A Low Clinical Drug Development Success

    Jun 1, 2021, 00:00

  • PBI13 Cost-Minimization Analysis and Budget Impact of Upadacitinib in the Treatment of Rheumatoid Arthritis in the Brazilian Public Health System

    Jun 1, 2021, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • Infectious Diseases - Methodological Statistical Research

    Jun 1, 2021, 00:00

  • PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System

    Jun 1, 2021, 00:00

  • PND7 Assessing the Comparative Efficacy of INP104 for Acute Treatment of Migraine Attacks: A Matching-Adjusted Indirect Comparison

    Jun 1, 2021, 00:00

  • PCN60 Healthcare Resource Utilization Burden in the Management of Triple-Class Exposed Patients With Relapsed/Refractory Multiple Myeloma: Results From the ITEMISE Study

    Jun 1, 2021, 00:00

  • PMD2 Laparoscopic Radiofrequency Ablation VS Laparoscopic Myomectomy in the Treatment of Symptomatic Uterine Leiomyomas: A Meta-Analysis of Randomized Controlled Trials

    Jun 1, 2021, 00:00

  • PNS39 Positive Decisions by Minister of Health on Increase of Ex-Factory Official Price of Publicly Funded Drugs in Poland Lack Content-Related Justifications - an Analysis of Quality of Justifications of Decisions on Increasing Prices of R ...

    Jun 1, 2021, 00:00

  • PNS2 Does the Type of Device Affect Usability or Conceptual Understanding of Patient-Reported Outcomes? Qualitative Evidence and Implications for Bring-Your-Own-Device (BYOD)

    Jun 1, 2021, 00:00

  • PMU41 Clinical Pharmacy Provider Dashboards May Prevent Avoidable Adverse Events and Reduce Total Cost of Care

    Jun 1, 2021, 00:00

  • PRS14 Evolution of Direct Medical Costs Associated with Respiratory Syncytial VIRUS Disease in Infants: A Retrospective Database Analysis from 2008 to 2017

    Jun 1, 2021, 00:00

  • PNS77 Transferring Health Technology Assessments from EARLY Adopter to Late Adopter Countries: Recommendations for the Implementation of CED Schemes in Central and Eastern European Countries

    Jun 1, 2021, 00:00

  • PNS45 Pricing and Reimbursement of Innovative Medicines: Challenges and Lessons from South-Eastern Europe

    Jun 1, 2021, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38 (current)
  • 39
  • 40
  • »